CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 181 enrolled
Drug / intervention
Tamsulosin +1 moredrug
Likely dose
Tamsulosin 0.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01741454
NCT01741454Phase 4Completed
CompareCT.gov

Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms

University of Wisconsin, Madison·interventional·Posted Dec 5, 2012·Updated Jul 10, 2019

In Brief

A Phase 4 clinical trial evaluating Tamsulosin and Tolterodine ER for Ureteral Obstruction. Completed, enrolled 181 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether combination therapy with Tolterodine ER and Tamsulosin is more effective than monotherapy with tamsulosin alone in reducing stent symptoms. The second purpose is to determine if people have less stent discomfort if they take these medications starting 2 weeks before the stent is placed The investigators hope to show that the addition of Tolterodine ER to Tamsulosin will provide added benefits in reducing stent symptoms in patients who have had unilateral placement of a ureteral stent.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUreteral Obstruction
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 5, 2012
Enrollment StartNov 1, 2012
Primary CompletionMar 30, 2018
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 13.6 years ago

Interventions

Tamsulosindrug

0.4 mg by mouth once per day.

Tolterodine ERdrug

4 mg by mouth once a day.